Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Anticancer Research

• Publication date

  2009-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 20032435
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunohistochemical detection of WT1 protein in endometrial cancer.

  2009cited by this paper
• Regulatory T cells and treatment of cancer.

  2008cited by this paper
• WT1 peptide vaccine for the treatment of cancer.

  2008cited by this paper
• Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

  2008cited by this paper
• WT1 (Wilms' Tumor 1) Peptide Immunotherapy for Renal Cell Carcinoma

  2007cited by this paper
• Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

  2007cited by this paper
• A tumor suppressor and oncogene: the WT1 story

  2007cited by this paper
• Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

  2006cited by this paper
• Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.

  2006cited by this paper
• A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.

  2006cited by this paper
• Immunohistochemical detection of WT1 protein in a variety of cancer cells

  2006cited by this paper
• Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

  2005cited by this paper
• Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

  2004cited by this paper
• WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone

  2004cited by this paper
• Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.

  2003cited by this paper
• Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues

  2002cited by this paper
• WT1 as a novel target antigen for cancer immunotherapy.

  2002cited by this paper
• Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

  2002cited by this paper
• Wilms’ Tumor GeneWT1: Its Oncogenic Function and Clinical Application

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Cytotoxic T-Lymphocyte Responses Elicited to Wilms' Tumor Gene WT1 Product by DNA Vaccination

  2000cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping

  1990cited by this paper
• Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.

  1990cited by this paper

• Nucleic acid‐based vaccine for ovarian cancer cells; bench to bedside

  2024cites this paper
• Identification of Tumor Antigens and Immune Subtypes of High-grade Serous Ovarian Cancer for mRNA Vaccine Development

  2023cites this paper
• The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review

  2023cites this paper
• The past, present, and future of immunotherapy for endometrial adenocarcinoma

  2023cites this paper
• Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors

  2022cites this paper
• Facts and hopes in immunotherapy of endometrial cancer.

  2022cites this paper
• Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy

  2021cites this paper
• Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies

  2021cites this paper
• Immuno-Oncology for Gynecologic Malignancies.

  2021cites this paper
• Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment

  2021cites this paper
• A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma

  2021cites this paper
• A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies

  2021cites this paper
• Immunotherapy in endometrial cancer: rationale, practice and perspectives

  2021cites this paper
• Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer

  2021cites this paper
• Diagnostic and Prognostic Role of WT1 Immunohistochemical Expression in Uterine Carcinoma: A Systematic Review and Meta-Analysis across All Endometrial Carcinoma Histotypes

  2020cites this paper
• Immunotherapy in Gynecological Malignancies

  2020cites this paper
• Immuno-oncology for Gynecologic Malignancies.

  2020cites this paper
• Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)

  2020cites this paper
• Endometrial cancer patients have high affinity antibodies for estrogen metabolite–receptor aggregate: A potential biomarker for EC

  2020cites this paper
• Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy

  2020cites this paper
• Wilms' Tumor 1 (WT1): The Vaccine for Cancer.

  2020cites this paper
• Development of Therapeutic Vaccines for Ovarian Cancer

  2020cites this paper
• Immunotherapy in endometrial cancer: new scenarios on the horizon

  2019cites this paper
• International Journal of Medical and Biomedical Studies (IJMBS)

  2019cites this paper
• Anti-Cancer Vaccine Activities of Zinc ( II ) for Cancer Prevention , Malignancy , Angiogenesis , and Metastasis with Cancer Progression

  2019cites this paper
• Antigen-specific active immunotherapy for ovarian cancer.

  2018cites this paper
• Loss of long noncoding RNA WT 1-AS is associated with better survival in early stage of cervical cancer

  2018cites this paper
• Functional characterisation of tumour-specific T cell responses in pancreatic cancer

  2017cites this paper
• Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade

  2017cites this paper
• IMMUNOTHERAPY IN ENDOMETRIAL CANCER

  2017cites this paper
• Immunology and Immunotherapy in Ovarian Cancer

  2017cites this paper
• Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification.

  2017cites this paper
• Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine

  2016cites this paper
• In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer

  2016cites this paper
• Identifying and targeting immunogenic mutations in ovarian cancer

  2016cites this paper
• Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.

  2016cites this paper
• Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines

  2016cites this paper
• WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives

  2016cites this paper
• Immunotherapy in endometrial cancer - an evolving therapeutic paradigm

  2015cites this paper
• Two distinct effector memory cell populations of WT1 (Wilms’ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients

  2015cites this paper
• WT1-, PRAME- and MSLN- specific immunity in epithelial ovarian cancer

  2014cites this paper
• Prognostic significance of WT1 expression in soft tissue sarcoma

  2014cites this paper
• The frequency and significance of WT-1 expression in serous endometrial carcinoma.

  2014cites this paper
• The WT1-gene – its role in tumourigenesis and prospects for developing a vaccine

  2014cites this paper
• The WT1 gene--its role in tumourigenesis and prospects for immunotherapeutic advances.

  2014cites this paper
• Past, present and future targets for immunotherapy in ovarian cancer.

  2014cites this paper
• Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies

  2014cites this paper
• Antigen-specific active immunotherapy for ovarian cancer.

  2014cites this paper
• Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.

  2013cites this paper
• WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial

  2013cites this paper
• Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

  2013cites this paper
• Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.

  2013cites this paper
• Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients

  2013cites this paper
• Wilms’ Tumor 1 Protein and Estrogen Receptor Beta Expression are Associated with Poor Outcomes in Uterine Carcinosarcoma

  2013cites this paper
• WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.

  2012cites this paper
• Immunotherapy in ovarian cancer

  2012cites this paper
• Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.

  2012cites this paper
• Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

  2012cites this paper
• Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine

  2011cites this paper
• Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression

  2011cites this paper
• Therapeutic cancer vaccines: are we there yet?

  2011cites this paper
• Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer

  2011cites this paper
• Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.

  2011cites this paper
• WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.

  2011cites this paper
• WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects.

  2010cites this paper
• Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.

  2010cites this paper